BTIG maintains USD 6 target for Neuronetics stock at EUR 1.69

Published on 10/15/2026 at 12:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neuronetics stock costs EUR 1.69 on October 15, 2026. Q2 revenue reached USD 41.57 million versus USD 37.77 million consensus.

Analyst view and reporting date

BTIG maintained a USD 6.00 price target on September 17, 2026.
Second-quarter revenue reached USD 41.57 million against USD 37.77 million consensus.
Neuronetics stock traded at EUR 1.69 at 12:40 p.m. CEST at Lang & Schwarz on October 15, 2026.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics (ISIN US64131A1051) was trading at EUR 1.69 at Lang & Schwarz on October 15, 2026 at 12:40 p.m. CEST. The latest analyst item in the 30-day window was BTIG's maintained USD 6.00 price target, dated September 17, 2026, according to Tormere. The contrast between the target and the euro quote makes the November reporting date the next concrete checkpoint.

BTIG keeps its USD 6 target

BTIG's maintained target is materially above the latest euro quote, but the analyst action itself was not a new increase. Tormere listed the September 17, 2026 note alongside a Buy rating and the USD 6.00 target. Neuronetics develops the NeuroStar Advanced Therapy System, an office-based transcranial magnetic stimulation treatment for major depressive disorder.

Three dates shaped the stock

On August 11, 2026, Neuronetics reported second-quarter revenue of USD 41.57 million and adjusted earnings per share of minus USD 0.05, while Business Quant showed consensus revenue of USD 37.77 million and consensus adjusted earnings per share of minus USD 0.12, a comparison carried by Business Quant. On August 14, 2026, 10 percent owner Jorey Chernett bought 14,000 shares at USD 3.16, according to Tormere. On September 17, 2026, BTIG maintained the USD 6.00 target.

What comes on November 3?

MarketBeat estimates that Neuronetics will report third-quarter 2026 results on November 3, 2026, before the market opens, with an 8:30 a.m. ET conference call, according to MarketBeat. Its estimate calls for revenue of USD 40.43 million and earnings per share of minus USD 0.08. Business Quant's consensus revenue estimate is USD 38.12 million, so the two published estimates differ by USD 2.31 million.

Price meets a key checkpoint

Stockanalysis identifies Neuronetics as a NASDAQ-listed medical device company with the ticker STIM and reporting currency USD, while the finance profile places it in Healthcare and Medical Devices. The company reported USD 41.57 million of second-quarter revenue, compared with USD 34.45 million in the first quarter, according to the standardized financial statements. The further course of trading is shown by the continuously updated real-time quote of Neuronetics stock.